Navigation Links
ImaginAb, Inc. and BZL Biologics, LLC Conclude Licensing Agreement for Imaging Rights to huJ591/Prostate-Specific Membrane Antigen (PSMA)

INGLEWOOD, Calif., Oct. 12 /PRNewswire/ -- ImaginAb, Inc. and BZL Biologics, LLC have concluded a sublicense of BZL's PSMA/huJ591 antibody technology for the field of diagnostic imaging for PET and SPECT. "ImaginAb is pleased to have completed this [sub]licensing agreement with BZL as we believe that huJ591 will form the basis of an excellent clinical product for the diagnosis and management of prostate cancer. BZL's technology has extensive human data, and we believe that huJ591 in conjunction with our antibody fragment technology will produce excellent imaging agents for PET," said Dr. Christian Behrenbruch, CEO of ImaginAb. Dr. Robert Reiter, Professor of Urology at UCLA and ImaginAb's Chief Medical Advisor further elaborated, "PSMA is an extremely significant target for prostate cancer and perhaps other solid tumors - we are excited to be validating antibody fragments against this target and plan to translate into the clinic in 2010."

"Our partnership with ImaginAb for antibody imaging with huJ591 is an important part of developing our PSMA intellectual property, and we believe that the imaging applications of our technology will result in a significant benefit to prostate cancer patient care by improving diagnostic accuracy and disease monitoring. We are also interested in working with ImaginAb to integrate imaging as part of a patient management paradigm for our PSMA-targeted therapeutics," commented Barry Silverstein, President of BZL Biologics.

About BZL Biologics

BZL Biologics, LLC is a privately held biotechnology company based in New York. Its lead program is based on antibody (Ab) targeting of PSMA, a unique cancer-related antigen that is present at high levels in all prostate cancers as well as the neo-vasculature of all types of solid tumors. This provides an exceptional platform on which to build very potent and exquisitely specific anti-tumor agents.

About ImaginAb

Founded in 2007 by UCLA Faculty (Dr. Rob Reiter and Dr. Anna Wu), ImaginAb, Inc. is an early-stage biotechnology company specializing in the development of engineered antibody fragments for diagnostic imaging and radioimmunotherapy. The company has a significant pipeline of clinical imaging agents under development oriented towards unmet needs in cancer and immunology. ImaginAb is also developing a range of pre-clinical (animal imaging) reagents for use with microPET and microSPECT systems.

SOURCE ImaginAb, Inc.

SOURCE ImaginAb, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Biologics, Derma Fillers are Key to Dermatological Drug Market Growth
2. LaVoie Group Adds Bio-Surgery Company, Pegasus Biologics, to Its Life Sciences Agency Roster
3. Workforce Alliance Concludes Three-Year Biotech Training Program
4. West Concludes Agreement with Nektar
5. Exelixis and GlaxoSmithKline Agree to Successfully Conclude Six-Year Discovery and Development Collaboration
6. Cephalon Concludes All Outstanding Federal and State Government Investigations into the Companys Sales and Promotional Practices
7. BioSyntech to conclude enrolment for pivotal BST-CarGel(R) trial in February 2009
8. Ipsen and Debiopharm Conclude an Exclusive Worldwide License Agreement for the Development and Commercialisation ff the Ipsens Proprietary CDC25[1] Inhibitor (IRC-083864 or Debio 0931), an Anti-Cancer Agent
9. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
10. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
11. BioWa Announces Licensing of BioWas POTELLIGENT(R) Technology by GlaxoSmithkline for Use in Antibody Research and Development
Post Your Comments:
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita Politecnica ... in people with peritoneal or pleural mesothelioma. Their findings are the subject of a ... , Diagnostic biomarkers are signposts in the blood, lung fluid or tissue of ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... Houston Methodist Willowbrook Hospital has signed ... to serve as their official health care provider. ... will provide sponsorship support, athletic training services, and ... volunteers, athletes and families. "We are ... and to bring Houston Methodist quality services and ...
(Date:6/23/2016)... YORK , June, 23, 2016  The Biodesign ... to envision new ways to harness living systems and ... Modern Art (MoMA) in New York City ... than 130 participating students, showcased projects at MoMA,s Celeste ... Paola Antonelli , MoMA,s senior curator of architecture ...
Breaking Biology Technology:
(Date:5/12/2016)... 12, 2016 , a brand ... overview results from the Q1 wave of its quarterly ... was consumers, receptivity to a program where they would ... health insurance company. "We were surprised to ... Michael LaColla , CEO of Troubadour Research, "primarily ...
(Date:4/26/2016)... and LONDON , April ... part of EdgeVerve Systems, a product subsidiary of ... today announced a partnership to integrate the Onegini ...      (Logo: ) ... their customers enhanced security to access and transact ...
(Date:4/14/2016)... , April 14, 2016 ... and Malware Detection, today announced the appointment of ... the new role. Goldwerger,s leadership appointment comes ... the heels of the deployment of its platform at ... behavioral biometric technology, which discerns unique cognitive and physiological ...
Breaking Biology News(10 mins):